A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together

NCT02085863 ↗

Phase 1 Completed 40 enrolled Teva Branded Pharmaceutical Products R&D, Inc.

RandomizedCrossoverDouble-blindOther

Summary

This is a single center, randomized, double blind, placebo controlled, 2-way crossover drug-drug interaction (DDI) study to assess the effect of laquinimod on the PK and PD of ethinylestradiol (EE) and levonorgestrel (LNG) a commonly used oral contraceptive combination.

Timeline

Start: 2014-02
Primary completion: 2014-09
Completion: 2014-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Laquinimod	Small molecule	0.6 mg	Oral

Indications

No indication recorded.